Allogeneic CAR-T therapies are developed from healthy donor cells and are stored “from the bar” for use in patients. This approach eliminates the need to develop a personalized therapy from a patient`s own cells, facilitates manufacturing, and reduces the time patients have to wait for CAR-T treatment. The allogeneic portfolio includes 16 preclinical T-cell therapy active ingredients and UCART19, an allogeneic car-T therapy currently in Phase 1 development for the treatment of acute lymphatic leukemia (LL). Through its remarkable partnerships, Allogene uses breakthrough technology platforms, including TALEN® gene editing technology, to advance its portfolio of immunonkological therapies.